Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PIONEER-1: A global pivotal study of Privosegtor for the treatment of acute onset of optic neuritis in a broad population consisting of patients with and without multiple sclerosis (MS)

Next Previous
Trial Profile

PIONEER-1: A global pivotal study of Privosegtor for the treatment of acute onset of optic neuritis in a broad population consisting of patients with and without multiple sclerosis (MS)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Privosegtor (Primary)
  • Indications Optic neuritis
  • Focus Registrational; Therapeutic Use
  • Acronyms PIONEER-1

Most Recent Events

  • 06 Jan 2026 According to Oculis pharma media release, sites activation is underway for this study, and enrollment is expected to begin shortly.
  • 12 Nov 2025 New trial record
  • 06 Oct 2025 According to Oculis pharma media release, dosing and patient enrollment criteria in PIONEER-1 and PIONEER-2 studies will mirror those of the positive Phase 2 ACUITY trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top